FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Tursz

Research Profile

Living Beings

Anatomy

Disorders

Chemicals & Drugs

Physiology

Procedures

Antineoplastic Combined Chemotherapy Protocols

Co-author Network

Publications

TOP 3
Thomas Tursz; Fabrice Andre; Vladimir Lazar; ludovic lacroix; Jean-Charles Soria
Implications of personalized medicine--perspective from a cancer center.
John Mendelsohn; Thomas Tursz; Richard L Schilsky; Vladimir Lazar
WIN Consortium--challenges and advances.
Sophie Viaud; Stéphanie Ploix; Valérie Lapierre; Clotilde Théry; Pierre-Henri Commere; Dominique Tramalloni; Kevin Gorrichon; Pauline Virault-Rocroy; Thomas Tursz; Olivier Lantz; Laurence Zitvogel; Nathalie Chaput
Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Tursz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Thomas Tursz; Fabrice Andre; Vladimir Lazar; ludovic lacroix; Jean-Charles Soria
Implications of personalized medicine--perspective from a cancer center.
Nature reviews. Clinical oncology 2011;8(3):177-83.
2011: John Mendelsohn; Thomas Tursz; Richard L Schilsky; Vladimir Lazar
WIN Consortium--challenges and advances.
Nature reviews. Clinical oncology 2011;8(3):133-4.
2011: Sophie Viaud; Stéphanie Ploix; Valérie Lapierre; Clotilde Théry; Pierre-Henri Commere; Dominique Tramalloni; Kevin Gorrichon; Pauline Virault-Rocroy; Thomas Tursz; Olivier Lantz; Laurence Zitvogel; Nathalie Chaput
Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2011;34(1):65-75.
2010: Hazem Assi; Gilles Missenard; Philippe Terrier; Cécile Le Pechoux; Sylvie Bonvalot; Daniel Vanel; J B Meric; Thomas Tursz; A Lecesne
Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial.
Current oncology (Toronto, Ont.) 2010;17(6):23-31.
2010: Moustapha Zoubir; Thomas Tursz; Cédric Ménard; Laurence Zitvogel; Nathalie Chaput
Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.
Endocrine, metabolic & immune disorders drug targets 2010;10(1):1-7.
2010: Sophie Viaud; Clotilde Théry; Stéphanie Ploix; Thomas Tursz; Valérie Lapierre; Olivier Lantz; Laurence Zitvogel; Nathalie Chaput
Dendritic cell-derived exosomes for cancer immunotherapy: what's next?
Cancer research 2010;70(4):1281-5.
2009: Houssem Benlalam; Abdelali JALIL; Meriem Hasmim; Baoxu Pang; Ryad Tamouza; Michèle Mitterrand; yann godet; Nathalie Lamerant; Caroline Robert; Marie-Françoise Avril; Jacques Neefjes; Thomas Tursz; Fathia Mami-Chouaib; Claudine Kieda; Salem Chouaib
Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(5):2654-64.
2009: Sophie Viaud; Magali Terme; Caroline Flament; Julien Taieb; Fabrice André; Sophie Novault; Bernard Escudier; Caroline Robert; Sophie Caillat-Zucman; Thomas Tursz; Laurence Zitvogel; Nathalie Chaput
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.
PloS one 2009;4(3):e4942.
2008: Jean Bénard; Gilda Raguénez; Audrey Kauffmann; Alexander Valent; Hugues Ripoche; Virginie Joulin; Bastien Job; Gisèle Danglot; Sabrina Cantais; Thomas Robert; Marie-José Terrier-Lacombe; Agnès Chassevent; Serge Koscielny; Matthias Fischer; Frank Berthold; Marc Lipinski; Thomas Tursz; Philippe Dessen; Vladimir Lazar; Dominique Valteau-Couanet
MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.
Molecular oncology 2008;2(3):261-71.
2008: Ulrik Ringborg; Marco Pierotti; Guy Storme; Thomas Tursz
Managing cancer in the EU: the Organisation of European Cancer Institutes (OECI).
European journal of cancer (Oxford, England : 1990) 2008;44(6):772-3.
2008: J Muret; M Yacoub; Philippe Terrier; F Drusch; Agnès Laplanche; C Gaudin; Catherine Richon; Cécile Le Péchoux; Axel Le Cesne; F J Lejeune; Thomas Tursz; Pierre Fouret; Sylvie Bonvalot; Salem Chouaib
p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19(4):793-800.
2008: Mahasti Saghatchian; Henk Hummel; Renée Otter; Dominique de Valeriola; Wim Van Harten; angelo paradiso; Bert Koot; Ulrik Ringborg; Thomas Tursz
Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OECI).
Tumori 2008;94(2):164-71.
2008: Ulrik Ringborg; Dominique de Valeriola; Wim van Harten; Antonio Llombart Bosch; Claudio Lombardo; Kenneth Nilsson; Thierry Philip; Marco A Pierotti; Peter Riegman; Mahasti Saghatchian; Guy Storme; Thomas Tursz; Dirk Verellen
Improvement of European translational cancer research. Collaboration between comprehensive cancer centers.
Tumori 2008;94(2):143-6.
2008: Kaouthar Khanfir; Agnes Chompret; Eric Frau; Eric Bloch-Michel; Thomas Tursz; Axel Le Cesne
An unusual variant of diffuse retinoblastoma in an adult.
Acta oncologica (Stockholm, Sweden) 2008;47(5):973-4.
2007: Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Alfredo Criollo; Carla Ortiz; Rosette Lidereau; Christophe Mariette; Nathalie Chaput; Jean-Paul Mira; Suzette Delaloge; Fabrice André; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy.
Immunological reviews 2007;220():47-59.
2007: Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernhard RYFFEL; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.
Nature medicine 2007;13(9):1050-9.
2007: R Conforti; Thomas Boulet; Gorana Tomasic; Estelle Taranchon; Rodrigo Arriagada; Marc Spielmann; Muriel Ducourtieux; Jean-Charles Soria; Thomas Tursz; Suzette Delaloge; Stefan Michiels; Fabrice Andre
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(9):1477-83.
2007: Evelyn Ullrich; Mathieu Bonmort; Grégoire Mignot; Nathalie Chaput; Julien Taieb; Cédric Ménard; Sophie Viaud; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.
Cancer research 2007;67(3):851-3.
2006: Ken A Olaussen; Ariane Dunant; Pierre Fouret; Elisabeth Brambilla; Fabrice André; Vincent Haddad; Estelle Taranchon; Martin Filipits; Robert Pirker; Helmut H Popper; Rolf Stahel; Laure Sabatier; Jean-Pierre Pignon; Thomas Tursz; Thierry Le Chevalier; Jean-Charles Soria
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
The New England journal of medicine 2006;355(10):983-91.
2006: Véronique Winnepenninckx; Vladimir Lazar; Stefan Michiels; Philippe Dessen; Marguerite Stas; Soledad R Alonso; Marie-Françoise Avril; Pablo L Ortiz-Romero; Thomas Robert; Ovidiu Balacescu; Alexander M M Eggermont; Gilbert Lenoir; Alain Sarasin; Thomas Tursz; Joost J van den Oord; Alain Spatz
Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Journal of the National Cancer Institute 2006;98(7):472-82.
2006: Julien Taieb; Nathalie Chaput; Cédric Ménard; Lionel Apetoh; Evelyn Ullrich; Mathieu Bonmort; Marie Péquignot; Noelia Casares; Magali Terme; Caroline Flament; Paule Opolon; Yann Lecluse; Didier Métivier; Elena Tomasello; Eric Vivier; François Ghiringhelli; François Martin; David Klatzmann; Thierry Poynard; Thomas Tursz; Graça Raposo; Hideo Yagita; Bernard Ryffel; Guido Kroemer; Laurence Zitvogel
A novel dendritic cell subset involved in tumor immunosurveillance.
Nature medicine 2006;12(2):214-9.
2005: Monique G Lê; Rodrigo Arriagada; Genevieve Contesso; Mohamed Cammoun; Frédérique Pfeiffer; Françoise Tabbane; Jacqueline Bahi; Michèle Dilaj; Marc Spielmann; Jean-Paul Travagli; Thomas Tursz; Nejib Mourali
Dermal lymphatic emboli in inflammatory and noninflammatory breast cancer: a French-Tunisian joint study in 337 patients.
Clinical breast cancer 2005;6(5):439-45.
2005: Laurence Zitvogel; Thomas Tursz
In vivo veritas.
Nature biotechnology 2005;23(11):1372-4.
2005: François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre-Emmanuel Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.
The Journal of experimental medicine 2005;202(8):1075-85.
2005: Julien Dômont; Timothy M Pawlik; Valérie Boige; Mathieu Rose; Jean-Christophe Weber; Paulo M Hoff; Thomas D Brown; daria zorzi; Luc Morat; Jean-Pierre Pignon; Asif Rashid; Daniel Jaeck; Laure Sabatier; Dominique Elias; Thomas Tursz; Jean-Charles Soria; Jean-Nicolas Vauthey
Catalytic subunit of human telomerase reverse transcriptase is an independent predictor of survival in patients undergoing curative resection of hepatic colorectal metastases: a multicenter analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):3086-93.
2005: Ariane Galaup; Claire Magnon; Valérie Rouffiac; Paule Opolon; David Opolon; Nathalie Lassau; Thomas Tursz; Michel Perricaudet; Frank Griscelli
Full kringles of plasminogen (aa 1-566) mediate complete regression of human MDA-MB-231 breast tumor xenografted in nude mice.
Gene therapy 2005;12(10):831-42.
2005: Rodrigo Arriagada; Monique G Lê; Marc Spielmann; Louis Mauriac; Jacques Bonneterre; Moïse Namer; Thierry Delozier; Catherine Hill; Thomas Tursz
Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(3):389-96.
2005: Rodrigo Arriagada; Marc Spielmann; serge koscielny; Thierry Le Chevalier; Thierry Delozier; Monique Rémé-Saumon; Muriel Ducourtieux; Thomas Tursz; Catherine Hill
Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer.
Acta oncologica (Stockholm, Sweden) 2005;44(5):458-66.
2004: Benjamin Besse; Céline Candé; Jean-Philippe Spano; Antoine Martin; David Khayat; Thierry Le Chevalier; Thomas Tursz; Laure Sabatier; Jean-Charles Soria; Guido Kroemer
Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(17):5665-9.
2004: Christophe Borg; Magali Terme; Julien Taïeb; Cédric Ménard; Caroline Flament; Caroline Robert; Koji Maruyama; Hiro Wakasugi; Eric Angevin; Kris Thielemans; Axel Le Cesne; Véronique Chung-Scott; Vladimir Lazar; Isabelle Tchou; Florent Crépineau; francois Lemoine; Jacky Bernard; Jonhantan A Fletcher; Ali G Turhan; Jean-Yves Blay; Alain Spatz; Jean-François Emile; Michael C Heinrich; Salaheddine Mécheri; Thomas Tursz; Laurence Zitvogel
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.
The Journal of clinical investigation 2004;114(3):379-88.
2004: Mark McCarthy; Roy M Poses; Mahasti Saghatchian; Gérard De Pouvourville; Thomas Tursz; Alastair M Gray
Cancer funding throughout the world.
The lancet oncology 2004;5(7):453-7.
2004: Nathalie Chaput; Noël Emile Célestin Schartz; Fabrice André; Julien Taïeb; Sophie Novault; Pierre Bonnaventure; Nathalie Aubert; Jacky Bernard; François Lemonnier; Miriam Merad; Gosse J Adema; Malcolm Adams; Maria Ferrantini; Antoine F Carpentier; Bernard Escudier; Thomas Tursz; Eric Angevin; Laurence Zitvogel
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(4):2137-46.
2004: Fabrice André; Nathalie Chaput; Noël Emile Célestin Schartz; Caroline Flament; Nathalie Aubert; Jacky Bernard; François Lemonnier; Graça Raposo; Bernard Escudier; Di-Hwei Hsu; Thomas Tursz; Sebastian Amigorena; Eric Angevin; Laurence Zitvogel
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(4):2126-36.
2004: Fabrice Andre; Bernard Escudier; Eric Angevin; Thomas Tursz; Laurence Zitvogel
Exosomes for cancer immunotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv141-4.
2004: Agnès Chompret; Caroline Kannengiesser; Michel Barrois; Philippe Terrier; Philippe Dahan; Thomas Tursz; Gilbert M Lenoir; Brigitte Bressac De-Paillerets
PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.
Gastroenterology 2004;126(1):318-21.
2003: Françoise Meunier; Nathalie Dubois; Anastassia Negrouk; Lesley-Ann Rea; Mahasti Saghatchian; Thomas Tursz; Richard Sullivan; Kate Law; Richard Tiner
Throwing a wrench in the works?
The lancet oncology 2003;4(12):717-9.
2003: Rodrigo Arriagada; Monique G Lê; Jean-Marc Guinebretière; Ariane Dunant; France Rochard; Thomas Tursz
Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(11):1617-22.
2003: Laurent Zelek; Antonio Llombart-Cussac; Philippe Terrier; Xavier Pivot; Jean-Marc Guinebretiere; Cécile Le Pechoux; Thomas Tursz; France Rochard; Marc Spielmann; Axel Le Cesne
Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2583-8.
2003: Ariane Galaup; Paule Opolon; Céline Bouquet; Hong Li; David Opolon; Marie-Christine Bissery; Thomas Tursz; Michel Perricaudet; Frank Griscelli
Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model.
Molecular therapy : the journal of the American Society of Gene Therapy 2003;7(6):731-40.
2003: Frank Griscelli; Paule Opolon; Patrick Saulnier; Fathia Mami-Chouaib; E Gautier; Hamid Echchakir; Eric Angevin; T Le Chevalier; V Bataille; Patrick Squiban; Thomas Tursz; Bernard Escudier
Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients.
Gene therapy 2003;10(5):386-95.
2002: Rodrigo Arriagada; Marc Spielmann; serge koscielny; Thierry Le Chevalier; Thierry Delozier; Muriel Ducourtieux; Thomas Tursz; Catherine Hill
Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(9):1378-86.
2002: Fabrice Andre; Noël Emile Célestin Schartz; Mojgan Movassagh; Caroline Flament; Patricia Pautier; Philippe Morice; Christophe Pomel; Catherine Lhomme; Bernard Escudier; Thierry Le Chevalier; Thomas Tursz; Sebastian Amigorena; Graça Raposo; Eric Angevin; Laurence Zitvogel
Malignant effusions and immunogenic tumour-derived exosomes.
Lancet 2002;360(9329):295-305.
2002: Thomas Tursz
An interview with Professor Thomas Tursz.
European journal of cancer (Oxford, England : 1990) 2002;38(3):319.
2001: Y Ikarashi; R Mikami; A Bendelac; Magali Terme; Nathalie Chaput; M Terada; Thomas Tursz; Eric Angevin; François A Lemonnier; Hiro Wakasugi; Laurence Zitvogel
Dendritic cell maturation overrules H-2D-mediated natural killer T (NKT) cell inhibition: critical role for B7 in CD1d-dependent NKT cell interferon gamma production.
The Journal of experimental medicine 2001;194(8):1179-86.
2001: J Wolfers; A Lozier; Graça Raposo; Armelle Regnault; Clotilde Théry; Carole Masurier; Caroline Flament; S Pouzieux; Florence Faure; Thomas Tursz; Eric Angevin; Sebastian Amigorena; Laurence Zitvogel
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming.
Nature medicine 2001;7(3):297-303.
2000: Jean-Charles Ahomadegbe; Sophie Tourpin; Mourad Kaghad; Laurent Zelek; Muriel Vayssade; Marie-Christine Mathieu; France Rochard; Marc Spielmann; Thomas Tursz; Daniel Caput; G Riou; Jean Bénard
Loss of heterozygosity, allele silencing and decreased expression of p73 gene in breast cancers: prevalence of alterations in inflammatory breast cancers.
Oncogene 2000;19(47):5413-8.
2000: Valérie Molinier-Frenkel; C Le Boulaire; Frédérique-Anne Le Gal; H Gahéry-Segard; Thomas Tursz; Jean-Gérard Guillet; Françoise Farace
Longitudinal follow-up of cellular and humoral immunity induced by recombinant adenovirus-mediated gene therapy in cancer patients.
Human gene therapy 2000;11(13):1911-20.
2000: Valérie Molinier-Frenkel; H Gahery-Segard; Majid Mehtali; C Le Boulaire; S Ribault; Pierre Boulanger; Thomas Tursz; Jean-Gérard Guillet; Françoise Farace
Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes.
Journal of virology 2000;74(16):7678-82.
2000: Laurence Zitvogel; Eric Angevin; Thomas Tursz
Dendritic cell-based immunotherapy of cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 3():199-205.
1999: Hector Ardila-Osorio; Bernard Clausse; Zohar Mishal; Joëlle Wiels; Thomas Tursz; Pierre Busson
Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells.
International journal of cancer. Journal international du cancer 1999;81(4):645-9.
1999: A Le Cesne; G Vassal; Françoise Farace; Marc Spielmann; T Le Chevalier; Eric Angevin; Dominique Valteau-Couanet; Karim Fizazi; I Cojean; A Llombard; Thomas Tursz; Bernard Escudier
Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(3):268-77.
1999: Nadine C Fernandez; A Lozier; Caroline Flament; Paola Ricciardi-Castagnoli; Dominique Bellet; M Suter; Michel Perricaudet; Thomas Tursz; E Maraskovsky; Laurence Zitvogel
Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.
Nature medicine 1999;5(4):405-11.
1999: F Sbih-Lammali; Bernard Clausse; Hector Ardila-Osorio; R Guerry; M Talbot; S Havouis; Laurent Ferradini; Jacques Bosq; Thomas Tursz; Pierre Busson
Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation.
Cancer research 1999;59(4):924-30.
1999: O Merimsky; P Terrier; A Stanca; Thierry Le Chevalier; Marc Spielmann; Thomas Tursz; Axel Le Cesne
Liver metastases from extremity soft tissue sarcoma.
American journal of clinical oncology 1999;22(1):70-2.
1998: Karim Fizazi; Nicole Dohollou; Jean-Yves Blay; Sylvie Guérin; Axel Le Cesne; Fabrice André; Pierre Pouillart; Thomas Tursz; B B Nguyen
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(12):3736-43.
1998: Antonio Llombart-Cussac; Xavier Pivot; A Rhor-Alvarado; Axel Le Cesne; Thierry Le Chevalier; Thomas Tursz; Marc Spielmann
First-line vinorelbine-mitoxantrone combination in metastatic breast cancer patients relapsing after an adjuvant anthracycline regimen: results of a phase II study.
Oncology 1998;55(5):384-90.
1998: C Capoulade; Brigitte Bressac De-Paillerets; I Lefrère; M Ronsin; Jean Feunteun; Thomas Tursz; Joëlle Wiels
Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.
Oncogene 1998;16(12):1603-10.
1998: Hanne Gahéry-Ségard; Françoise Farace; D Godfrin; Jessintha Gaston; Renée Lengagne; Thomas Tursz; Pierre Boulanger; Jean-Gérard Guillet
Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity.
Journal of virology 1998;72(3):2388-97.
1997: Hanne Gahéry-Ségard; Valérie Molinier-Frenkel; C Le Boulaire; Patrick Saulnier; Paule Opolon; Renée Lengagne; E Gautier; A Le Cesne; Laurence Zitvogel; Alain Venet; C Schatz; M Courtney; T Le Chevalier; Thomas Tursz; Jean-Gérard Guillet; Françoise Farace
Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products.
The Journal of clinical investigation 1997;100(9):2218-26.
1997: S Taga; Karine Carlier; Zohar Mishal; C Capoulade; M Mangeney; Yann Lécluse; Dominique Coulaud; Cecile Tétaud; L L Pritchard; Thomas Tursz; Joëlle Wiels
Intracellular signaling events in CD77-mediated apoptosis of Burkitt's lymphoma cells.
Blood 1997;90(7):2757-67.
1997: Bernard Clausse; K Fizazi; V Walczak; C Tetaud; Joëlle Wiels; Thomas Tursz; Pierre Busson
High concentration of the EBV latent membrane protein 1 in glycosphingolipid-rich complexes from both epithelial and lymphoid cells.
Virology 1997;228(2):285-93.
1996: Karim Fizazi; J Feuillard; Axel Le Cesne; Philippe Terrier; M Raphael; P Pouillart; Thomas Tursz
Soft tissue sarcomas in HIV-infected adult patients.
European journal of cancer (Oxford, England : 1990) 1996;32A(10):1812-4.
1996: Thierry Le Chevalier; D Brisgand; Jean-Louis Pujol; Jean-Yves Douillard; A Monnier; Alain Rivière; P Chomy; A Le Groumellec; P Ruffie; M Gottfried; M H Gaspard; Christine Chevreau; Vicente Alberola; S Cigolari; F Besson; A Martinez; M Besenval; P Berthaud; Thomas Tursz
[Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].
Bulletin du cancer 1996;83(5):385-94.
1995: F Thomas; Rodrigo Arriagada; Marc Spielmann; H Mouriesse; Thierry Le Chevalier; F Fontaine; Thomas Tursz
Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
Cancer 1995;76(11):2286-90.
1995: S Taga; M Mangeney; Thomas Tursz; Joëlle Wiels
Differential regulation of glycosphingolipid biosynthesis in phenotypically distinct Burkitt's lymphoma cell lines.
International journal of cancer. Journal international du cancer 1995;61(2):261-7.
1995: M Mangeney; G Rousselet; S Taga; Thomas Tursz; Joëlle Wiels
The fate of human CD77+ germinal center B lymphocytes after rescue from apoptosis.
Molecular immunology 1995;32(5):333-9.
1995: S Taga; C Tétaud; M Mangeney; Thomas Tursz; Joëlle Wiels
Sequential changes in glycolipid expression during human B cell differentiation: enzymatic bases.
Biochimica et biophysica acta 1995;1254(1):56-65.
1994: Salem Chouaib; Jihed Chehimi; L Bani; N Genetet; Thomas Tursz; F Gay; G Trinchieri; Fathia Mami-Chouaib
Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(26):12659-63.
1994: C Biguet; N Wakasugi; Z Mishal; A Holmgren; Salem Chouaib; Thomas Tursz; H Wakasugi
Thioredoxin increases the proliferation of human B-cell lines through a protein kinase C-dependent mechanism.
The Journal of biological chemistry 1994;269(46):28865-70.
1994: C Toussaint; J Izzo; Marc Spielmann; S Merle; F May-Levin; Jean-Pierre Armand; D Lacombe; Thomas Tursz; M Sunderland; Guy G. Chabot
Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(10):2102-12.
1994: Karim Fizazi; I Cojean; Axel Le Cesne; L Kayitalire; Thierry Le Chevalier; Thomas Tursz; Marc Spielmann
[Soft tissue sarcomas: general review].
Bulletin du cancer 1994;81(10):835-52.
1994: Marc Spielmann; T Dorval; F Turpin; E Antoine; M Jouve; F Maylevin; D Lacombe; J Rouesse; P Pouillart; Thomas Tursz
Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(9):1764-70.
1994: Q Zhang; L Brooks; Pierre Busson; F Wang; D Charron; E Kieff; A B Rickinson; Thomas Tursz
Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line.
European journal of immunology 1994;24(6):1467-70.
1994: Lélia Delamarre; Claudine Pique; Danielle Pham; Thomas Tursz; Marie-Christine Dokhélar
Identification of functional regions in the human T-cell leukemia virus type I SU glycoprotein.
Journal of virology 1994;68(6):3544-9.
1994: S Roithmann; Claudine Pique; Axel Le Cesne; Lélia Delamarre; Danielle Pham; Thomas Tursz; Marie-Christine Dokhélar
The open reading frame I (ORF I)/ORF II part of the human T-cell leukemia virus type I X region is dispensable for p40tax, p27rex, or envelope expression.
Journal of virology 1994;68(5):3448-51.
1994: Claudine Pique; F Saal; J Périès; Danielle Pham; Thomas Tursz; Marie-Christine Dokhélar
Functional comparison between HTLV-I envelopes originating from TSP/HAM or ATL cell lines.
Journal of acquired immune deficiency syndromes 1994;7(4):319-24.
1994: A Zyad; J Bénard; Thomas Tursz; Robert Clarke; Salem Chouaib
Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.
Cancer research 1994;54(3):825-31.
1993: Esteban Cvitkovic; M Bachouchi; H Boussen; Pierre Busson; G Rousselet; R Mahjoubi; P Flores; Thomas Tursz; Jean-Pierre Armand; Nacer Azli
Leukemoid reaction, bone marrow invasion, fever of unknown origin, and metastatic pattern in the natural history of advanced undifferentiated carcinoma of nasopharyngeal type: a review of 255 consecutive cases.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(12):2434-42.
1993: G Rousselet; M Bachouchi; Pierre Busson; Florent de Vathaire; H Wakasugi; Guy Schwaab; Nacer Azli; Jean-Pierre Armand; Esteban Cvitkovic; Thomas Tursz
Clinical implications of the serum level of CD23 in patients with undifferentiated nasopharyngeal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2143-9.
1993: M Mangeney; C A Lingwood; S Taga; B Caillou; Thomas Tursz; Joëlle Wiels
Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen.
Cancer research 1993;53(21):5314-9.
1993: P Berthaud; I Eugène-Jolchine; Marc Spielmann; Thierry Le Chevalier; Thomas Tursz
[Phase I trial of recombinant human granulocyte-macrophage colony stimulating factor. Results in patients with advanced tumors].
Bulletin du cancer 1993;80(5):418-30.
1993: Alain BERNHEIM; G Rousselet; L Massaad; Pierre Busson; Thomas Tursz
Cytogenetic studies in three xenografted nasopharyngeal carcinomas.
Cancer genetics and cytogenetics 1993;66(1):11-5.
1993: Claudine Pique; Danielle Pham; Thomas Tursz; Marie-Christine Dokhélar
The cytoplasmic domain of the human T-cell leukemia virus type I envelope can modulate envelope functions in a cell type-dependent manner.
Journal of virology 1993;67(1):557-61.
1993: Thomas Tursz
[Hematopoietic growth factors: from laboratory to clinical practice].
Pathologie-biologie 1993;41(1):41.
1992: A Zyad; Didier Branellec; Y Mahé; Thomas Tursz; Salem Chouaib
The development of human tumor-cell resistance to TNF-alpha does not confer resistance to cytokine-induced cellular cytotoxic mechanisms.
International journal of cancer. Journal international du cancer 1992;52(6):953-8.
1992: L Kayitalire; F Thomas; Thierry Le Chevalier; C Toussaint; Thomas Tursz; Marc Spielmann
Phase II study of a combination of elliptinium and vinblastine in metastatic breast cancer.
Investigational new drugs 1992;10(4):303-7.
1992: Y Mahé; K Hirose; Bernard Clausse; Salem Chouaib; Thomas Tursz; B Mariamé
Heterogeneity among human nasopharyngeal carcinoma cell lines for inflammatory cytokines mRNA expression levels.
Biochemical and biophysical research communications 1992;187(1):121-6.
1992: G Rousselet; Thomas Tursz
CD23 and the Epstein-Barr virus.
Research in immunology 1992;143(4):456-9.
1992: Pierre Busson; Q Zhang; J M Guillon; Christopher D Gregory; L S Young; Bernard Clausse; M Lipinski; A B Rickinson; Thomas Tursz
Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells.
International journal of cancer. Journal international du cancer 1992;50(6):863-7.
1992: Genevieve Contesso; A Llombart-Bosch; Philippe Terrier; A Peydro-Olaya; Michel Henry-Amar; Odile Oberlin; Jean-Louis Habrand; Jean Dubousset; Thomas Tursz; Marc Spielmann
Does malignant small round cell tumor of the thoracopulmonary region (Askin tumor) constitute a clinicopathologic entity? An analysis of 30 cases with immunohistochemical and electron-microscopic support treated at the Institute Gustave Roussy.
Cancer 1992;69(4):1012-20.
1992: Claudine Pique; Danielle Pham; Thomas Tursz; Marie-Christine Dokhélar
Human T-cell leukemia virus type I envelope protein maturation process: requirements for syncytium formation.
Journal of virology 1992;66(2):906-13.
1992: P Berthaud; Thierry Le Chevalier; P Ruffie; P Baldeyrou; Rodrigo Arriagada; F Besson; Thomas Tursz
Phase I-II study of vinorelbine (Navelbine) plus cisplatin in advanced non-small cell lung cancer.
European journal of cancer (Oxford, England : 1990) 1992;28A(11):1863-5.
1991: Joëlle Wiels; M Mangeney; C Tétaud; Thomas Tursz
Sequential shifts in the three major glycosphingolipid series are associated with B cell differentiation.
International immunology 1991;3(12):1289-300.
1991: Claudine Pique; Y Mahé; C Scamps; C Tétaud; Thomas Tursz; Joëlle Wiels
Analysis of phenotypic and functional changes during ganglioside-induced inhibition of human T cell proliferation.
Molecular immunology 1991;28(11):1163-70.
1991: Thierry Le Chevalier; F Thomas; R Subirana; P Baldeyrou; P Ruffie; Rodrigo Arriagada; M Chazard; Thomas Tursz
A phase II study of the combination of carboplatin and ifosfamide in previously untreated metastatic small cell lung carcinoma.
Cancer 1991;67(12):2980-3.
1991: Y Mahé; H Wakasugi; C Scamps; Salem Chouaib; Thomas Tursz
Role of calcium on interleukin-1 production by monocytes: its relevance during T cell proliferation.
Lymphokine and cytokine research 1991;10(3):165-72.
1991: M Mangeney; Y Richard; Dominique Coulaud; Thomas Tursz; Joëlle Wiels
CD77: an antigen of germinal center B cells entering apoptosis.
European journal of immunology 1991;21(5):1131-40.
1991: Thomas Tursz; T Dorval; P Berthaud; M Jouve; Marie-Françoise Avril; E Garcia-Giralt; Thierry Le Chevalier; Marc Spielmann; D Sevin; T Palangie
[Phase I trial of a recombinant human interleukin 2. Results in patients with disseminated solid tumors].
Presse médicale (Paris, France : 1983) 1991;20(6):250-4.
1991: L Ferradini; S Miescher; M Stoeck; Pierre Busson; C Barras; N Cerf-Bensussan; M Lipinski; V von Fliedner; Thomas Tursz
Cytotoxic potential despite impaired activation pathways in T lymphocytes infiltrating nasopharyngeal carcinoma.
International journal of cancer. Journal international du cancer 1991;47(3):362-70.
1991: Marc Spielmann; J Berille; David Khayat; J P Bizzari; C Jacquillat; Thomas Tursz
[Fotemustine: a pilot phase II trial in sarcoma of the soft tissues].
Bulletin du cancer 1991;78(5):453-6.
1991: Thomas Tursz
[Some realisations in the class of anti-tumor drugs].
Annales pharmaceutiques françaises 1991;49(6):299-306.
1991: G Rousselet; Marc Billaud; Pierre Busson; G Lenoir; Thomas Tursz
CD23 and epithelial cells.
Monographs in allergy 1991;29():186-95.
1991: Junji Yodoi; Thomas Tursz
ADF, a growth-promoting factor derived from adult T cell leukemia and homologous to thioredoxin: involvement in lymphocyte immortalization by HTLV-I and EBV.
Advances in cancer research 1991;57():381-411.
1990: Yutaka Tagaya; H Wakasugi; Hiroshi Masutani; H Nakamura; Shingo Iwata; Akira Mitsui; Shingo Fujii; N Wakasugi; Thomas Tursz; Junji Yodoi
Role of ATL-derived factor (ADF) in the normal and abnormal cellular activation: involvement of dithiol related reduction.
Molecular immunology 1990;27(12):1279-89.
1990: N Wakasugi; Yutaka Tagaya; H Wakasugi; Akira Mitsui; M Maeda; Junji Yodoi; Thomas Tursz
Adult T-cell leukemia-derived factor/thioredoxin, produced by both human T-lymphotropic virus type I- and Epstein-Barr virus-transformed lymphocytes, acts as an autocrine growth factor and synergizes with interleukin 1 and interleukin 2.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(21):8282-6.
1990: Françoise Farace; C Mathiot; M Brandely; Thomas Tursz; T Dorval; P Pouillart; Frédéric Triebel; T Hercend; W H Fridman
Phase I trial with recombinant interleukin-2 (rIL-2): immune activation by rIL-2 alone or following pretreatment with recombinant interferon-gamma.
Clinical and experimental immunology 1990;82(2):194-9.
1990: Thomas Tursz
[Growth factors and anti-growth factors in tumor therapy].
Pathologie-biologie 1990;38(8):786-7.
1990: M Cordier; Alain Calender; Marc Billaud; U Zimber; G Rousselet; O Pavlish; Jacques Banchereau; Thomas Tursz; Georg W Bornkamm; Gilbert M Lenoir
Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
Journal of virology 1990;64(3):1002-13.
1990: G Rousselet; Pierre Busson; Marc Billaud; J M Guillon; C Scamps; H Wakasugi; G Lenoir; Thomas Tursz
Structure and regulation of the blast-2/CD23 antigen in epithelial cells from nasopharyngeal carcinoma.
International immunology 1990;2(12):1159-66.
1989: P Berthaud; Thierry Le Chevalier; J Berille; P Herait; P Baldeyrou; Thomas Tursz; Rodrigo Arriagada; Marc Spielmann; M Hayat
Phase II study of pirarubicin in advanced non-small cell lung cancer.
European journal of cancer & clinical oncology 1989;25(10):1507-8.
1989: Marc Billaud; Pierre Busson; D Huang; N Mueller-Lantzch; G Rousselet; O Pavlish; H Wakasugi; J M Seigneurin; Thomas Tursz; Gilbert M Lenoir
Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2.
Journal of virology 1989;63(10):4121-8.
1989: P Berthaud; Thierry Le Chevalier; J Berille; P Herait; P Baldeyrou; Thomas Tursz; Rodrigo Arriagada; Marc Spielmann; M Hayat
Phase II study of pirarubicin in advanced non-small cell lung cancer.
European journal of cancer & clinical oncology 1989;25(9):1337-8.
1989: C Bensimon; N Wakasugi; Yutaka Tagaya; K Takakura; Junji Yodoi; Thomas Tursz; H Wakasugi
Two distinct affinity binding sites for IL-1 on human cell lines.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(4):1168-74.
1989: H Wakasugi; N Wakasugi; Thomas Tursz; Yutaka Tagaya; Junji Yodoi
Production of an IL-1-like factor by 3B6 EBV-infected B cells.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(7):2569-70.
1989: C Bensimon; H Wakasugi; N Wakasugi; S Jitsukawa; Thomas Tursz
A monoclonal antibody recognizing 68- to 75-kilodalton protein(s) associated with the human IL-1 receptor.
Journal of immunology (Baltimore, Md. : 1950) 1989;142(7):2290-8.
1988: Y Mahé; J P Piau; N Wakasugi; Thomas Tursz; Gérard Gacon; H Wakasugi
Comparison of interleukin 2 and 12-O-tetradecanoylphorbol 13-acetate as signals for protein kinase C activation in purified human T lymphocytes.
European journal of immunology 1988;18(12):2029-36.
1988: H Wakasugi; Y Mahé; S Huet; Laurence Boumsell; Alain Bernard; Thomas Tursz
Comparison of signals delivered through CD3 and CD2 for T-cell activation: the role of calcium influx and interleukin 1.
Human immunology 1988;23(3):163-78.
1988: Françoise Farace; M T Mitjavila; A Betaieb; M C Dokhelar; Joëlle Wiels; Y Finale; NELLY KIEFFER; J Breton-Gorius; William Vainchenker; Thomas Tursz
New hematopoietic differentiation antigens detected by anti-K562 monoclonal antibodies.
Cancer research 1988;48(20):5759-65.
1988: Pierre Busson; Gérard Ganem; P Flores; F Mugneret; Bernard Clausse; B Caillou; K Braham; H Wakasugi; M Lipinski; Thomas Tursz
Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas.
International journal of cancer. Journal international du cancer 1988;42(4):599-606.
1988: Christopher D Gregory; C F Edwards; A Milner; Joëlle Wiels; M Lipinski; Martin Rowe; Thomas Tursz; Alan B Rickinson
Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus.
International journal of cancer. Journal international du cancer 1988;42(2):213-20.
1988: Lawrence S Young; Christopher W Dawson; D Clark; H Rupani; Pierre Busson; Thomas Tursz; A Johnson; Alan B Rickinson
Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
The Journal of general virology 1988;69 ( Pt 5)():1051-65.
1988: A Bettaieb; Françoise Farace; M T Mitjavila; Z Mishal; M C Dokhelar; Thomas Tursz; J Breton-Gorius; William Vainchenker; NELLY KIEFFER
Use of a monoclonal antibody (GA3) to demonstrate lineage restricted O-glycosylation on leukosialin during terminal erythroid differentiation.
Blood 1988;71(5):1226-33.
1988: K Braham; S Junqua; Thomas Tursz; J B Le Pecq; M Lipinski
Kinetic analysis of choriocarcinoma cell intoxication induced by ricin and ricin A chain immunotoxin.
Cancer research 1988;48(4):806-11.
1988: M Lipinski; Thomas Tursz
[Contribution of immunology and molecular biology].
Bulletin du cancer 1988;75(5):417-21.
1988: Pierre Busson; K Braham; Bernard Clausse; Thomas Tursz
Constitutive expression of HLA class II antigens on EBV positive malignant cells from nasopharyngeal carcinoma: possible involvement in T cell infiltration.
Cancer detection and prevention 1988;12(1-6):363-8.
1987: Pierre Busson; K Braham; Gérard Ganem; F Thomas; D Grausz; M Lipinski; H Wakasugi; Thomas Tursz
Epstein-Barr virus-containing epithelial cells from nasopharyngeal carcinoma produce interleukin 1 alpha.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(17):6262-6.
1987: Christopher D Gregory; Thomas Tursz; C F Edwards; C Tetaud; M Talbot; B Caillou; Alan B Rickinson; M Lipinski
Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(1):313-8.
1987: H Wakasugi; C Bensimon; Y Mahé; Pierre Busson; Laurence Rimsky; Didier Fradelizi; Jacques Bertoglio; Thomas Tursz
B-cell-derived interleukin-1.
Annales de l'Institut Pasteur. Immunology 1987;138(4):599-603.
1987: H Wakasugi; Laurence Rimsky; Y Mahe; Azza Kamel; Didier Fradelizi; Thomas Tursz; J Bertoglio
Epstein-Barr virus-containing B-cell line produces an interleukin 1 that it uses as a growth factor.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(3):804-8.
1987: S Junqua; Joëlle Wiels; Thomas Tursz; J B Le Pecq
Antitumor activity against L1210 mouse leukemia of immunotoxins containing a monoclonal antibody to the glycolipid globotriaosylceramide.
Immunology letters 1987;14(2):167-72.
1987: M Lipinski; K Braham; I Philip; Joëlle Wiels; T Philip; C Goridis; G M Lenoir; Thomas Tursz
Neuroectoderm-associated antigens on Ewing's sarcoma cell lines.
Cancer research 1987;47(1):183-7.
1986: Françoise Farace; NELLY KIEFFER; B Caillou; W Vainchenker; Thomas Tursz; M C Dokhelar
A 93-kDa glycoprotein expressed on human cultured monocytes and dendritic reticulum cells defined by an anti-K562 monoclonal antibody.
European journal of immunology 1986;16(12):1521-6.
1986: Laurence Rimsky; H Wakasugi; Pascual Ferrara; Philippe Robin; J Capdevielle; Thomas Tursz; Didier Fradelizi; Jacques Bertoglio
Purification to homogeneity and NH2-terminal amino acid sequence of a novel interleukin 1 species derived from a human B cell line.
Journal of immunology (Baltimore, Md. : 1950) 1986;136(9):3304-10.
1986: M Lipinski; K Braham; I Philip; Joëlle Wiels; T Philip; K Dellagi; C Goridis; G M Lenoir; Thomas Tursz
Phenotypic characterization of Ewing sarcoma cell lines with monoclonal antibodies.
Journal of cellular biochemistry 1986;31(4):289-96.
1985: A Balana; Joëlle Wiels; C Tetaud; Zohar Mishal; Thomas Tursz
Induction of cell differentiation in Burkitt lymphoma lines. BLA: a glycolipid marker of B-cell differentiation.
International journal of cancer. Journal international du cancer 1985;36(4):453-60.
1984: Joëlle Wiels; S Junqua; P Dujardin; J B Le Pecq; Thomas Tursz
Properties of immunotoxins against a glycolipid antigen associated with Burkitt's lymphoma.
Cancer research 1984;44(1):129-33.
1983: M Lipinski; K Braham; J M Caillaud; C Carlu; Thomas Tursz
HNK-1 antibody detects an antigen expressed on neuroectodermal cells.
The Journal of experimental medicine 1983;158(5):1775-80.
1982: Thomas Tursz; M C Dokhelar; M Lipinski; J L Amiel
Low natural killer cell activity in patients with malignant lymphoma.
Cancer 1982;50(11):2333-5.
1982: Joëlle Wiels; G M Lenoir; M Fellous; M Lipinski; J C Salomon; C Tetaud; Thomas Tursz
A monoclonal antibody with anti-Burkitt lymphoma specificity. I. Analysis of human haematopoietic and lymphoid cell lines.
International journal of cancer. Journal international du cancer 1982;29(6):653-8.
1982: F Ben Ayed; D Bellet; N Badri; M Spielmann; Jean Pierre Droz; Thomas Tursz; J L Amiel
[Factors of severity in placental choriocarcinoma].
Journal de gynécologie, obstétrique et biologie de la reproduction 1982;11(4):487-9.
1982: M C Dokhelar; U Testa; William Vainchenker; Y Finale; C Tetaud; P Salem; Thomas Tursz
NK cell sensitivity of the leukemic K 562 cells; effect of sodium butyrate and hemin induction.
Journal of immunology (Baltimore, Md. : 1950) 1982;128(1):211-6.
1982: F Ben Ayed; D Bellet; N Badri; M Spielmann; Jean Pierre Droz; Thomas Tursz; J L Amiel
[Recurrences of placental choriocarcinoma].
Journal de gynécologie, obstétrique et biologie de la reproduction 1982;11(3):383-4.
1982: Thomas Tursz; F Ben Ayed; Jean Pierre Droz; M Spielmann; J L Amiel
[Salvage chemotherapy in resistant malignant lymphomas (author's transl)].
Bulletin du cancer 1982;69(1):28-32.
1981: J Rouesse; Thomas Tursz; Thierry Le Chevalier; D Huertas; J L Amiel; G Brule; B Callet; Jean Pierre Droz; P M Voisin; H Sancho-Garnier; J B Le Pecq; C Paoletti
[N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)].
La Nouvelle presse médicale 1981;10(24):1997-9.
1981: Jacques Rouëssé; D Huertas; H Sancho-Garnier; Thierry Le Chevalier; J L Amiel; G Brulé; Thomas Tursz; J M Mondésir
[2 N methyl 9 hydroxy-ellipticine in treatment of metastatic breast cancers (author's transl)].
Bulletin du cancer 1981;68(5):437-41.
1980: J L Amiel; G Michel; Jean Pierre Droz; Thomas Tursz; F Ben Ayed
[Second laparotomy in cancers of the ovary treated with chemotherapy. 17 cases (author's transl)].
La Nouvelle presse médicale 1980;9(47):3605-8.
1980: J L Amiel; Jean Pierre Droz; Thomas Tursz; F Ben Ayed; J Gastiaburu; J Rouesse
[Cis-diamminated-dichloroplatinum (CDDP) in the chemotherapy of testicular dysembryomas and choriocarcinomas (author's transl)].
Journal d'urologie 1980;86(6):463-5.